Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15839684 | 1.00 | BACE1 (1.00) | BACE1BCHETACR1FPR2REN | |
| SCHEMBL15839628 | 0.88 | BACE1 (0.78) | BACE1CTSDBACE2KCNH2 | |
| SCHEMBL17260359 | 0.88 | BACE1 (0.78) | BACE1CTSDBACE2KCNH2 | |
| SCHEMBL15839630 | 0.88 | BACE1 (0.78) | BACE1KCNH2 | |
| SCHEMBL15839626 | 0.86 | BACE1 (0.75) | BACE1BCHETACR1FPR2REN | |
| SCHEMBL15826211 | 0.85 | BACE1 (0.74) | BACE1BACE2KCNH2 | |
| SCHEMBL15825505 | 0.84 | BACE1 (0.81) | BACE1RENCTSDBACE2ALDH1A1 | |
| SCHEMBL15826155 | 0.84 | BACE1 (0.78) | BACE1TACR1ALDH1A1 | |
| SCHEMBL15825666 | 0.84 | BACE1 (0.78) | BACE1TACR1ALDH1A1 | |
| SCHEMBL15839685 | 0.84 | BACE1 (0.81) | BACE1RENCTSDBACE2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935256-B1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2018-01-24 | — | — | EP | disclosed |
| US-9475784-B2 | 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150329506-A1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329506-A1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BACE1, APP, BACE2 | BACE1 1/4885BCHE 79/4885TACR1 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.